BCR-ABL Mutation-Guided Therapy for CML Blast Crisis: A Case Report | Zendy

Benjamin N. Ostendorf | Zendy; Hendrik Nogai | Zendy; Claudia D. Baldus | Zendy; Thomas Burmeister | Zendy; Renate Arnold | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

BCR-ABL Mutation-Guided Therapy for CML Blast Crisis: A Case Report

Author(s) -

Benjamin N. Ostendorf,

Hendrik Nogai,

Claudia D. Baldus,

Thomas Burmeister,

Renate Arnold

Publication year - 2015

Publication title -

biomarker insights

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.075

H-Index - 31

ISSN - 1177-2719

DOI - 10.4137/bmi.s22279

Subject(s) - blast crisis , medicine , myeloid leukemia , tyrosine kinase , targeted therapy , oncology , transplantation , stem cell , phenotype , cancer research , immunology , bioinformatics , cancer , biology , genetics , gene , receptor

The management of patients with chronic myeloid leukemia (CML) in advanced phases is challenging and requires the consideration of different treatment approaches, including targeted therapy with tyrosine kinase inhibitors, cytotoxic chemotherapy, and allogeneic stem cell transplantation. Here, we present the case of a patient with CML in mixed phenotype blast phase illustrating the integration of these strategies and demonstrating the need for close monitoring of treatment response in order to individually adjust treatment regimens.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research